First human test of mRNA flu shot shows promise
NCT ID NCT05426174
Summary
This early-stage study tested the safety and immune response of a new mRNA-based flu vaccine in healthy adults. Researchers gave 233 participants different dose levels of the experimental vaccine and monitored them for side effects and antibody production for a year. The goal was to gather initial data to see if this new type of flu vaccine is safe and triggers a protective immune response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AES - DRS - Optimal Research_Site 8400001
Peoria, Illinois, 61614-4885, United States
-
AES - DRS - Optimal Research_Site 8400002
Melbourne, Florida, 32934-8172, United States
-
AES - DRS - Optimal Research_Site 8400007
Huntsville, Alabama, 35802, United States
-
Central Phoenix Medical Clinic, LLC_Site: 8400010
Phoenix, Arizona, 85020, United States
-
Optimal Research San Diego, LLC_Site: 8400009
San Diego, California, 92108, United States
-
Synexus Clinical Research_Site 8400003
Cincinnati, Ohio, 45236, United States
Conditions
Explore the condition pages connected to this study.